These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Lipid metabolism in hormonal contraception].
    Author: Manuilova IA, Dubnitskaia LV, Aleksandrovskaia TN, Shallaeva VV.
    Journal: Akush Ginekol (Mosk); 1985 Aug; (9):51-4. PubMed ID: 2933983.
    Abstract:
    A comparative study of lipid metabolism was conducted in women using oral contraceptives (OCs). 64 women, aged 20-35, who had been taking OCs for 6-12 months were studied. The pills contained various doses of estrogenic and gestagenic components. Before taking OCs, the women did not show any symptoms of lipid metabolism disorders. Over the course of this study, the status of lipid metabolism was assessed from the concentration of total cholesterol, triglycerides, and alphacholesterol in the blood. The coefficients of atherogenesis were also measured. Results indicate that none of the OCs under study (Non-ovlon, Ovidan, Rigevidon, and Triquilar) induces pathological hyperlipidemia. However, they do cause some changes in the blood levels of low-and high-density lipoproteins; this effect is more pronounced for OCs with high estrogen doses. Therefore, Ovidan and Non-ovlon, containing 50 ug of estrogen, can only be used by healthy women under 35 years of age who have no lipid metabolism disorders. Triquilar and Rigevidon are recommended for women who are more likely to develop such disorders.
    [Abstract] [Full Text] [Related] [New Search]